Suppr超能文献

原发灶不明癌:临床管理中的挑战与进展

Cancer of Unknown Primary: Challenges and Progress in Clinical Management.

作者信息

Laprovitera Noemi, Riefolo Mattia, Ambrosini Elisa, Klec Christiane, Pichler Martin, Ferracin Manuela

机构信息

Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, 40126 Bologna, Italy.

Department of Life Sciences and Biotechnologies, University of Ferrara, 44121 Ferrara, Italy.

出版信息

Cancers (Basel). 2021 Jan 25;13(3):451. doi: 10.3390/cancers13030451.

Abstract

Distant metastases are the main cause of cancer-related deaths in patients with advanced tumors. A standard diagnostic workup usually contains the identification of the tissue-of-origin of metastatic tumors, although under certain circumstances, it remains elusive. This disease setting is defined as cancer of unknown primary (CUP). Accounting for approximately 3-5% of all cancer diagnoses, CUPs are characterized by an aggressive clinical behavior and represent a real therapeutic challenge. The lack of determination of a tissue of origin precludes CUP patients from specific evidence-based therapeutic options or access to clinical trial, which significantly impacts their life expectancy. In the era of precision medicine, it is essential to characterize CUP molecular features, including the expression profile of non-coding RNAs, to improve our understanding of CUP biology and identify novel therapeutic strategies. This review article sheds light on this enigmatic disease by summarizing the current knowledge on CUPs focusing on recent discoveries and emerging diagnostic strategies.

摘要

远处转移是晚期肿瘤患者癌症相关死亡的主要原因。标准的诊断检查通常包括确定转移性肿瘤的原发组织,尽管在某些情况下,这仍然难以实现。这种疾病状态被定义为原发灶不明的癌症(CUP)。CUP约占所有癌症诊断的3% - 5%,其特点是临床行为侵袭性强,是一个真正的治疗挑战。由于无法确定原发组织,CUP患者无法获得基于特定证据的治疗选择或参与临床试验,这显著影响了他们的预期寿命。在精准医学时代,表征CUP的分子特征,包括非编码RNA的表达谱,对于增进我们对CUP生物学的理解和确定新的治疗策略至关重要。本文通过总结关于CUP的现有知识,重点关注近期发现和新兴诊断策略,来揭示这种神秘的疾病。

相似文献

1
Cancer of Unknown Primary: Challenges and Progress in Clinical Management.
Cancers (Basel). 2021 Jan 25;13(3):451. doi: 10.3390/cancers13030451.
2
"Metastatic Cancer of Unknown Primary" or "Primary Metastatic Cancer"?
Front Oncol. 2020 Jan 17;9:1546. doi: 10.3389/fonc.2019.01546. eCollection 2019.
3
Progress in refining the clinical management of cancer of unknown primary in the molecular era.
Nat Rev Clin Oncol. 2020 Sep;17(9):541-554. doi: 10.1038/s41571-020-0359-1. Epub 2020 Apr 29.
5
Molecular diagnosis of the tissue of origin in cancer of unknown primary site: useful in patient management.
Curr Treat Options Oncol. 2013 Dec;14(4):634-42. doi: 10.1007/s11864-013-0257-1.
8
Insights from the genetic and transcriptional characterization of a cancer of unknown primary (CUP).
EMBO Mol Med. 2020 Jul 7;12(7):e12685. doi: 10.15252/emmm.202012685. Epub 2020 Jun 17.
9
Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?
Cancer Treat Rev. 2021 Jun;97:102204. doi: 10.1016/j.ctrv.2021.102204. Epub 2021 Apr 5.

引用本文的文献

1
Utility of Germline, Somatic and ctDNA Testing in Adults With Cancer.
Cancer Med. 2025 Aug;14(15):e71080. doi: 10.1002/cam4.71080.
2
GPSai: A Clinically Validated AI Tool for Tissue of Origin Prediction during Routine Tumor Profiling.
Cancer Res Commun. 2025 Sep 1;5(9):1477-1489. doi: 10.1158/2767-9764.CRC-25-0171.
4
Metastatic Colorectal Cancer Presenting as Spinal Cord Compression and Mimicking Tuberculosis.
Cureus. 2025 May 11;17(5):e83928. doi: 10.7759/cureus.83928. eCollection 2025 May.
5
Advancements in Diagnostics and Therapeutics for Cancer of Unknown Primary in the Era of Precision Medicine.
MedComm (2020). 2025 Apr 16;6(5):e70161. doi: 10.1002/mco2.70161. eCollection 2025 May.
6
Cancer of Unknown Primary With Squamous Cell Carcinoma Phenotype Presenting as Isolated Axillary Mass.
Cureus. 2025 Mar 5;17(3):e80094. doi: 10.7759/cureus.80094. eCollection 2025 Mar.
7
Carcinoma of Unknown Primary: Integrating Timely Interventions and Molecular Advancements for Improved Outcomes.
Cureus. 2024 Dec 19;16(12):e76035. doi: 10.7759/cureus.76035. eCollection 2024 Dec.
8
Small cell lung carcinoma metastatic to the stomach: Commonly overlooked, limited treatment options.
World J Gastroenterol. 2024 Dec 28;30(48):5198-5204. doi: 10.3748/wjg.v30.i48.5198.
10
Cancer of unknown primary and BRAF V600E meeting the BEACON combination: A case report.
Mol Clin Oncol. 2024 Sep 30;21(6):88. doi: 10.3892/mco.2024.2786. eCollection 2024 Dec.

本文引用的文献

2
Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers.
Cell. 2020 Aug 20;182(4):1044-1061.e18. doi: 10.1016/j.cell.2020.07.009. Epub 2020 Aug 13.
4
Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care.
JAMA Oncol. 2020 Jan 1;6(1):84-91. doi: 10.1001/jamaoncol.2019.3985.
5
Comprehensive management of HPV-related squamous cell carcinoma of the head and neck of unknown primary.
Head Neck. 2019 Oct;41(10):3700-3711. doi: 10.1002/hed.25858. Epub 2019 Jul 13.
6
The currently declining incidence of cancer of unknown primary.
Cancer Epidemiol. 2019 Aug;61:139-141. doi: 10.1016/j.canep.2019.06.006. Epub 2019 Jun 26.
8
How I treat cancers of unknown primary.
ESMO Open. 2019 May 10;4(Suppl 2):e000502. doi: 10.1136/esmoopen-2019-000502. eCollection 2019.
9
Familial cancer of unknown primary.
Int J Clin Oncol. 2019 Oct;24(10):1328-1331. doi: 10.1007/s10147-019-01491-1. Epub 2019 Jun 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验